Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction.
Piccolo R, Galasso G, Eitel I, Dominguez-Rodriguez A, Iversen AZ, Gu YL, Abreu-Gonzalez P, de Smet BJ, Esposito G, Windecker S, Thiele H, Piscione F. Piccolo R, et al. Among authors: iversen az. Am J Cardiol. 2016 Dec 15;118(12):1798-1804. doi: 10.1016/j.amjcard.2016.08.068. Epub 2016 Sep 13. Am J Cardiol. 2016. PMID: 27756477
Field triage reduces treatment delay and improves long-term clinical outcome in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Pedersen SH, Galatius S, Hansen PR, Mogelvang R, Abildstrom SZ, Sørensen R, Davidsen U, Galloe A, Abildgaard U, Iversen A, Bech J, Madsen JK, Jensen JS. Pedersen SH, et al. J Am Coll Cardiol. 2009 Dec 8;54(24):2296-302. doi: 10.1016/j.jacc.2009.06.056. J Am Coll Cardiol. 2009. PMID: 19958965 Free article.
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS. Iversen A, et al. J Interv Cardiol. 2011 Apr;24(2):105-11. doi: 10.1111/j.1540-8183.2010.00616.x. Epub 2010 Dec 22. J Interv Cardiol. 2011. PMID: 21175845 Free article. Clinical Trial.
Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ, Galatius S, Abildgaard U, Galloe A, Hansen PR, Pedersen S, Engstroem T, Jensen JS. Iversen AZ, et al. Cardiology. 2011;120(1):43-9. doi: 10.1159/000333117. Epub 2011 Nov 23. Cardiology. 2011. PMID: 22122887 Free article. Clinical Trial.
Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient data pooled analysis of randomised studies.
Piccolo R, Gu YL, Iversen AZ, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Eitel I, Abreu-Gonzalez P, Thiele H, Piscione F. Piccolo R, et al. Among authors: iversen az. Heart. 2012 May 24. doi: 10.1136/heartjnl-2011-301101. Epub 2012 May 24. Heart. 2012. PMID: 22397943 Retracted.
58 results